No products in the cart.
Pre-made Isatuximab benchmark antibody ( Whole mAb, anti-CD38 therapeutic antibody, Anti-ADPRC1/ADPRC 1 Antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-ab-279
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Isatuximab biosimilar, Whole mAb, Anti-CD38 Antibody: Anti-ADPRC1/ADPRC 1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Isatuximab, sold under the brand name Sarclisa, is a monoclonal antibody (mAb) medication for the treatment of multiple myeloma.
| Products Name (INN Index) | Pre-Made Isatuximab biosimilar, Whole mAb, Anti-CD38 Antibody: Anti-ADPRC1/ADPRC 1 therapeutic antibody |
|---|---|
| INN Name | Isatuximab |
| Target | CD38 |
| Format | Whole mAb |
| Derivation | Chimeric (Mouse/Human) |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Approved |
| Est. Status | Active |
| 100% SI Structure | 4cmh:BC |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2014 |
| Year Recommended | 2015 |
| Companies | ImmunoGen,Huntsman Cancer Institute,Roche,Sanofi |
| Conditions Approved | Multiple myeloma |
| Conditions Active | Acute myeloid leukaemia,Precursor cell lymphoblastic leukaemia-lymphoma,Colorectal cancer,Diffuse large B cell lymphoma,Hodgkin's disease,Solid tumours,Urogenital cancer |
| Conditions Discontinued | Non-small cell lung cancer,Prostrate cancer,T-cell lymphoma |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | CD38 |
| Package |
Previous slide
Next slide
